Phase 1Active, not recruiting
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
A Phase 1 Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin's Lymphoma (VIVID)
- Sponsor
- Sana Biotechnology (Industry)
- Enrolment
- 6 planned
- Conditions
- Non Hodgkin's Lymphoma; Large B-cell Lymphoma
- Interventions
- SC262
- Ages
- adults, older adults
- Registry
- NCT06285422
Full record on ClinicalTrials.gov
From the registry
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Primary outcomes
- Evaluate safety and tolerability of SC262
History
Study completion expected
Primary completion
Last registry update
Started
Registered